Veradermics has secured $820 million in funding to advance VDPHL01, an oral extended-release formulation of minoxidil designed to treat pattern hair loss in men and women. The company reports positive Phase 2 data in women and plans confirmatory Phase 3 readouts in men by late 2026, positioning itself to become the first FDA-approved oral, non-hormonal hair loss treatment.
Key Points
- Phase 2 study showed women gained ~23 hairs/cm² after six months; 90% reported improvement
- Extended-release delivery aims to eliminate sharp bloodstream spikes that raised cardiac safety conc
- Male Phase 3 trials enrolling 1,000+ participants; topline results expected H2 2026
Longevity Analysis
Hair loss represents a measurable marker of systemic function that extends beyond appearance—it reflects hormonal balance, nutritional status, and stress physiology. An oral therapeutic that addresses the underlying pharmacokinetics of minoxidil (steady release rather than sharp spikes) while maintaining cardiac safety could expand treatment access to underserved populations. The clinical evidence emerging from large, controlled trials will clarify whether systemic delivery of this agent can reliably reverse follicle miniaturization without the safety trade-offs that have historically confined oral minoxidil to off-label use. For practitioners, success here would provide a non-hormonal option for patients where topical adherence or efficacy has failed.
Original published by Longevity.Technology, by Kyle Umipig.